Skip to main content
. Author manuscript; available in PMC: 2020 Aug 18.
Published in final edited form as: Am J Clin Oncol. 2016 Dec;39(6):535–544. doi: 10.1097/COC.0000000000000331

TABLE 5.

A 25-Year-Old Woman With Stage IIA Nodular Sclerosing Hodgkin Lymphoma With Bilateral Supraclavicular and Mediastinal (7 cm in Widest Diameter) Involvement; Normal ESR. Interim PET/CT Scan Demonstrates Deauville 3 in Mediastinum

Treatment Rating Comments
Chemotherapy and ISRT 9
Chemotherapy and IFRT 6
Chemotherapy alone 6
Duration of ABVD (if chemotherapy given alone)
 2 cycles 2
 4 cycles 5
 6 cycles 7 This option assumes interim PET was negative after 4 cycles of chemotherapy
Duration of ABVD (combined modality)
 2 cycles 5 This option may be appropriate but there was disagreement among panel members on the appropriateness rating as defined by the panel’s median rating
 4 cycles 6
 6 cycles 4
Dose of radiation therapy (combined modality)
 20 Gy 5 This option may be appropriate but there was disagreement among panel members on the appropriateness rating as defined by the panel’s median rating
 30 Gy 7
 30 Gy + 6 Gy boost to mediastinum 5

Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.

ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; ESR, erythrocyte sedimentation rate; IFRT, involved field radiation therapy; ISRT, involved site radiation therapy; PET/CT, positron emission tomography/computed tomography.